Recent News
An Inaccurate Mesothelioma Prognosis Can Result in Wrong Treatment
Mesothelioma is not easy to diagnose. Symptoms often mimic other ailments and patients often do not make the connection between asbestos exposure and their illness. Once mesothelioma is diagnosed, patients…
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Purpose:This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.
Screening for Mesothelioma: Detecting Mesothelioma Before Symptoms
Diagnosing mesothelioma in the early stages has proven to be difficult. Biomarkers and diagnostic procedures are the most common way of determining this cancer’s existence, but if mesothelioma could be…
Risk Factors From Intraperitoneal Chemotherapy Could Be Determined By Early Biomarker
Peritoneal mesothelioma is an extremely rare form of mesothelioma that affects the abdominal lining, or peritoneum. Caused by asbestos exposure, peritoneal mesothelioma can be difficult to diagnose because symptoms are…
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Purpose:The trial is an open-label, parallel group, multicentre trial that will recruit a total of 30 patients with malignant pleural mesothelioma. The trial will be conducted in 2 phases: a non-randomised safety phase and a randomised phase. The safety phase will consist of a lead-in cohort of 6 patients treated with ONCOS 102 and pemetrexed/cisplatin. The randomised phase will not commence until the DSMB has deemed the safety lead-in data appropriate for continuation. A total of 24 patients will be included in the randomised phase; 14 patients will be randomised to receive ONCOS 102 and pemetrexed/cisplatin, and 10 patients will receive pemetrexed/cisplatin alone. The trial’s main objectives are determination of safety, immune activation, clinical response and the correlation between clinical outcome and the immunological data.
ONCOS-102 Passes Safety Evaluation in Phase I Clinical Trials, Phase II Clinical Trial Recommended
A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering…
Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers
Purpose CK-301 is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objective of this study is to assess the safety, tolerability and preliminary efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.
Legitimate Data and Research is Required for Treatment Approval
For cancer patients who have little success with traditional chemotherapy and radiation treatments, immunotherapy treatments are becoming known alternatives – working with the body’s own immune system to become stronger…
Pleural Catheter vs. Pleurodesis
Symptoms for pleural mesothelioma are typically centered on lung function breathing, with shortness of breath (dyspnea), pleural effusion (fluid build-up), and pain in the chest being the primary indicators. There…
Funding Needed for Lung Cancer Awareness and Research – How You Can Help
As November draws to a close, so does Lung Cancer Awareness Month, but that doesn’t mean we should forget about this devastating cancer that affects hundreds of thousands of people…
